Maxim Group Reaffirms Hold Rating for NovaBay Pharma (NBY)
NovaBay Pharma (NYSE:NBY) traded down 5.79% on Thursday, hitting $4.39. The stock had a trading volume of 126,040 shares. The stock has a 50-day moving average of $3.57 and a 200-day moving average of $2.73. NovaBay Pharma has a one year low of $1.75 and a one year high of $9.50. The company’s market cap is $49.39 million.
NovaBay Pharma (NYSE:NBY) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.06. The company earned $2.70 million during the quarter, compared to analysts’ expectations of $1.76 million. Equities analysts expect that NovaBay Pharma will post ($1.77) earnings per share for the current fiscal year.
About NovaBay Pharma
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Stock Ratings for NovaBay Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharma and related stocks with our FREE daily email newsletter.